Cortechs.ai has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its NeuroQuant 5.0 software for use with brain MR imaging.
This update allows radiologists to improve segmentation for amyloid-related imaging abnormalities (ARIA) in patients undergoing anti-amyloid treatment for Alzheimer’s disease. NeuroQuant 5.0 improves visualization and calculations of lesions through deep learning-based technology, according to the firm. The results provide insights that support more precise and data-driven patient care for managing neurological conditions like traumatic brain injury, cerebral amyloid angiopathy, ARIA-E, and ARIA-H.
